Related Experiment Video
Updated: Apr 5, 2026

Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization
Published on: November 19, 2014
Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment
M T van de Bilt1, C M Prado1, E P B Ojopi1
1Laboratory of Neurosciences, Department of Psychiatry, Faculty of Medicine, University of São Paulo, Brazil.
Abstract:
Evidence validating the influence of the cytochrome P450 (CYP) 2D6 and 2C19 enzymes genetic polymorphisms in the response to antipsychotics is scarce. We examined the hypothesis that a higher prevalence of CYP2D6 and/or CYP2C19 ultra rapid metabolizers might be found among refractory schizophrenia patients. Three groups were studied: refractory and non-refractory schizophrenia patients, and healthy controls. Participants were genotyped for CYP2D6 and CYP2C19 polymorphisms and classified in metabolic phenotypes. No between-group differences in the distribution of the phenotypes were found. Therefore, our findings do not support the CYPs 2D6 and 2C19 genotyping in the prediction of therapeutic response in schizophrenia.
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Psychosis: Goals of Pharmacotherapy
Drug toxicity: Idiosyncratic Reactions
Pharmacogenetics of Drug Metabolism: Overview
Antipsychotic Drugs: Typical and Atypical Agents

